These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Buchert R, Thomasius R, Petersen K, Wilke F, Obrocki J, Nebeling B, Wartberg L, Zapletalova P, Clausen M. Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):188-99. PubMed ID: 16133393 [Abstract] [Full Text] [Related]
13. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Buchert R, Obrocki J, Thomasius R, Väterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M. Nucl Med Commun; 2001 Aug; 22(8):889-97. PubMed ID: 11473208 [Abstract] [Full Text] [Related]
14. Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender. de Win MM, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W. Psychopharmacology (Berl); 2004 May; 173(3-4):376-82. PubMed ID: 14726997 [Abstract] [Full Text] [Related]
15. Are ecstasy induced serotonergic alterations overestimated for the majority of users? Szigeti B, Winstock AR, Erritzoe D, Maier LJ. J Psychopharmacol; 2018 Jul; 32(7):741-748. PubMed ID: 29733742 [Abstract] [Full Text] [Related]
19. Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907. Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M. Neuropsychopharmacology; 2012 May 07; 37(6):1465-73. PubMed ID: 22353758 [Abstract] [Full Text] [Related]